Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-645-1 | CAS number: 536-74-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From October 29, 2021 to February 24, 2022
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study performed according to OECD Guideline No.423 and under GLP compliance (GLP deviation due to the lack of verification of the the test item concentration in the dose applied during this test. Without impact on the reliability of the results generated).
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
- Report date:
- 2022
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- December 17th, 2001
- Deviations:
- yes
- Remarks:
- Daily examination carried at 50 hrs and 44 min, instead of at 48 ± 2 hrs after administration of the test item and relative humidity lower than 30% registered during 2 periods of the study. No impact on the conclusion of the study.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Phenylacetylene
- EC Number:
- 208-645-1
- EC Name:
- Phenylacetylene
- Cas Number:
- 536-74-3
- Molecular formula:
- C8H6
- IUPAC Name:
- ethynylbenzene
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- SPF Caw
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (F-69210 Saint-Germain-Nuelles)
- Age at study initiation: female (8 or 9 weeks old)
- Weight at study initiation: female (185-230 g)
- Housing: group of three in solid-bottomed clear polycarbonate cages with a stainless-steel mesh lid. Each cage contains sawdust bedding which was changed at least 2 times a week. Each cage was installed in conventional air-conditioned animal husbandry
- Diet : foodstuff (ENVIGO – 2914C / 2016). Food was removed on day 1 and then redistributed 4 hours after the test item administration
- Water : tap-water from public distribution system, ad libitum
- Acclimation period: at least five days
ENVIRONMENTAL CONDITIONS
- Temperature : 19°C to 25°C
- Humidity : 30% to 70%
- Air changes (per hr): 10 per hour
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- -Dose volume applied: 2.15 mL/kg
-Rationale: oral administration was used as this is one possible route of human exposure during manufacture, handling and use of the test article. - Doses:
- 300 and 2000 mg/kg bw
- No. of animals per sex per dose:
- 6 animals/dose
- Control animals:
- no
- Details on study design:
- The test item PHENYLACETYLENE was administered by gavage to a group of 6 female Sprague Dawley rats at the dose of 300 mg/kg body weight (step 1 and step 2), then a group of 6 female Sprague Dawley rats at the dose of 2000 mg/kg body weight (step 3 and step 4).
- Daily examination
Systematic examinations were carried out to identify any behavioural or toxic effects on the major physiological functions 30 minutes, 1 hour ± 6 minutes, 3 hours ± 30 minutes, 4 hours ± 30 minutes, 24 and 48 hours ± 2 hours after administration of the test item and continued daily for 14 days. This examination focuses particularly on a list of symptoms, recorded as "present" or "absent" on the observation sheet. These observations were compared to historical control data.
Observations and a mortality report were then carried out every day for 14 days.
- Periodical examinations
The animals were weighed on day D0 (just before administering the test item) then on day 2, day 7, and day 14. Weight changes were calculated and recorded. The body weight evolution of animals treated with the test item is compared with the body weight evolution of the control group.
- Examination at the end of the test
On Day 14, the animals were euthanized with sodium pentobarbital (Dolethal®). Macroscopic observations were entered on individual autopsy sheets. Only those organs likely to be modified in cases of acute toxicity were examined. No organ was removed and preserved in view to microscopic examinations.
Results and discussion
- Preliminary study:
- None
Effect levelsopen allclose all
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- 2 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality was noted in animals treated at the dose of 300 mg/kg body weight (step 1 and step 2).
Two mortalities (1 animal in each step) were noted in animals treated at the dose of 2000 mg/kg body weight, on day 1. - Clinical signs:
- other:
- Body weight:
- other body weight observations
- Remarks:
- The body weight evolution of the animals (treated at the dose of 300 mg/kg body weight) remained normal during the study.
- Gross pathology:
- The macroscopic examination of the animals (treated at the dose of 300 mg/kg body weight) at the end of the study did not reveal treatment related changes.
Any other information on results incl. tables
Group treated at 2000 mg/kg bw (Steps 3 and 4):
Two mortalities (1 animal in each step) were noted in animals treated at the dose of 2000 mg/kg body weight, on day 1. No clinical signs related to the administration of the test item were observed before the mortalities. The macroscopic examination of the animals revealed thin (2/2) and red (1/2) stomach wall with the stomach swollen with air (1/2). It was also noted areas of redness on proventricular wall, orange fundic wall (1/2) and air inside duodenum, jejunum and ileon (1/2).
In surviving animals of Step 3 (2/3), it was noted a decrease of spontaneous activity (2/2), a decrease of muscle tones (2/2) and mydriasis (1/2) from the first hours after the treatment. On day 1, a decrease of righting reflex (1/2), a loss of balance when walking (2/2) and an increase of lachrymation (2/2) were noted. Chromodacryorrhea (1/2) was also noted on day 2. The animals recovered a normal activity on day 2.
In surviving animals of Step 4 (2/3), it was noted a decrease or absence of spontaneous activity (2/2) and piloerection (2/2) from the first hours after the treatment until day 2. On day 1, a decrease of muscle tones (2/2), a decrease of Preyer’s reflex (2/2), an increase of lachrymation (2/2) and dyspnea (2/2) were noted. Chromodacryorrhea (2/2) was also observed from day 2 to day 5. The animals recovered a normal activity on day 6. The mean body weight evolution of the animal revealed a decrease of 5% of body weight at D2 versus D0. Then, the body weight evolution remains normal. The macroscopic examination of the animal at the end of the study did not reveal treatment related changes.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the test conditions, the oral LD50 of the test item PHENYLACETYLENE is higher than 2000 mg/kg body weight and lower than 5000 mg/kg body weight.
In accordance with the OECD Test Guideline No. 423, the LD50 cut-off of the test item may be considered as 2500 mg/kg body weight by oral route in the rat.
Therefore, the test item PHENYLACETYLENE is not classified according to the Regulation (EC) No. 1272/2008 (CLP) and no signal word or hazard statement is required. - Executive summary:
The test item PHENYLACETYLENE was administered to a group of 6 female Sprague Dawley rats at the dose of 300 mg/kg body weight, then a group of 6 female Sprague Dawley rats at the dose of 2000 mg/kg body weight.
The experimental protocol was established according to the official method as defined in the OECD Test Guideline No. 423 dated December 17th, 2001.Group treated at 300 mg/kg (Steps 1 and 2):
No mortality was noted in animals treated at the dose of 300 mg/kg body weight.
No clinical signs related to the administration of the test item were observed during the study.
The body weight evolution of the animals remained normal during the study.
The macroscopic examination of the animal at the end of the study did not reveal treatment related changes.Group treated at 2000 mg/kg (Steps 3 and 4):
- Two mortalities (1 animal in each step) were noted in animals treated at the dose of 2000 mg/kg body weight, on day 1. No clinical signs related to the administration of the test item were observed before the mortalities. The macroscopic examination of the animals revealed thin (2/2) and red (1/2) stomach wall with the stomach swollen with air (1/2). It was also noted areas of redness on proventricular wall, orange fundic wall (1/2) and air inside duodenum, jejunum and ileon (1/2).
- In surviving animals of Step 3 (2/3), it was noted a decrease of spontaneous activity (2/2), a decrease of muscle tones (2/2) and mydriasis (1/2) from the first hours after the treatment. On day 1, a decrease of righting reflex (1/2), a loss of balance when walking (2/2) and an increase of lachrymation (2/2) were noted. Chromodacryorrhea (1/2) was also noted on day 2. The animals recovered a normal activity on day 2.
- In surviving animals of Step 4 (2/3), it was noted a decrease or absence of spontaneous activity (2/2) and piloerection (2/2) from the first hours after the treatment until day 2. On day 1, a decrease of muscle tones (2/2), a decrease of Preyer’s reflex (2/2), an increase of lachrymation (2/2) and dyspnea (2/2) were noted. Chromodacryorrhea (2/2) was also observed from day 2 to day 5. The animals recovered a normal activity on day 6. The mean body weight evolution of the animal revealed a decrease of 5% of body weight at D2 versus D0. Then, the body weight evolution remains normal. The macroscopic examination of the animal at the end of the study did not reveal treatment related changes.Under the test conditions, the oral LD50 of the test item PHENYLACETYLENE is higher than 2000 mg/kg body weight and lower than 5000 mg/kg body weight. In accordance with the OECD Test Guideline No. 423, the LD50 cut-off of the test item may be considered as 2500 mg/kg body weight by oral route in the rat.
Therefore, the test item PHENYLACETYLENE is not classified according to the Regulation (EC) No. 1272/2008 (CLP) and no signal word or hazard statement is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.